Clear Search

Showing 6 results for “Desai A” published 2022.

December 2022

Efficacy and Safety of Dapagliflozin in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction by Baseline Glycaemic Status (DELIVER): a Subgroup Analysis from an International, Multicentre, Double-blind, Randomised, Placebo-controlled Trial

Lancet Diabetes Endocrinol. 2022;10:869–881 DOI: 10.1016/S2213-8587(22)00308-4

Dapagliflozin was shown to be highly efficacious in patients with HFmrEF and HFpEF in the DELIVER trial. However, whether the benefits of dapagliflozin are observed across glycaemia categories has not been previously reported.

more…

November 2022

Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial

JAMA Cardiol. 2022; online ahead of print DOI: 10.1001/jamacardio.2022.3750

Dapagliflozin was recently shown to reduce CV death or worsening HF events in patients with HF with mildly reduced or preserved ejection fraction in the DELIVER trial. This prespecified secondary analysis of DELIVER examined the timeline to onset of clinical benefit with dapagliflozin.

more…

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER

JAMA Cardiol. 2022; online ahead of print DOI: 10.1001/jamacardio.2022.3736

In a prospective, patient-level pooled meta-analysis of the DAPA-HF and DELIVER trials, dapagliflozin-associated reductions in CV mortality in patients with HF appeared to be principally due to lower rates of sudden death and HF death, regardless of EF.

more…

October 2022
September 2022

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

J Am Coll Cardiol. 2022; online ahead of print DOI: 10.1016/j.jacc.2022.07.021

This prespecified analysis of the DELIVER trial found that dapagliflozin had beneficial effects on cardiovascular (CV) outcomes in patients with heart failure (HF) with mildly reduced or preserved left ventricular ejection fraction (LVEF) who were enrolled during or following hospitalisation.

more…